Why Small Molecules Are Back in the Spotlight

Drugmakers pivot to scalable small molecule therapies in rare disease pipelines

19 Mar 2026

A shift is under way in the US rare disease drug market, as small molecule therapies regain prominence in orphan drug pipelines.

Industry data indicates that small molecules now account for a leading share of the most valuable rare disease treatments in development. The change reflects a growing focus on therapies that are simpler to manufacture and distribute than complex biologics.

For much of the past decade, gene and cell therapies dominated development for rare conditions. While these approaches remain important, their production often depends on specialised facilities and intricate processes, which can delay commercial rollout.

Small molecules, by contrast, rely on established manufacturing systems. This allows for more predictable production timelines and easier scaling, factors that are gaining weight as companies seek to bring treatments to market more efficiently.

Cost considerations are also shaping strategy. Small molecule therapies are typically cheaper to produce, which may support more sustainable pricing. This comes as high-cost rare disease treatments face closer scrutiny from insurers and policymakers concerned about affordability.

The shift does not suggest a retreat from advanced therapies. Instead, drugmakers are adopting a more balanced approach, choosing technologies based on the needs of specific conditions. Gene therapies remain central for certain genetic disorders, while small molecules offer practical advantages in others.

This broader mix is reshaping development strategies. Companies are placing greater emphasis not only on scientific promise but also on manufacturing feasibility and patient access when building their pipelines.

As the market evolves, the renewed focus on small molecules points to a wider industry recalibration. The ability to deliver treatments at scale may become as important as scientific innovation in determining which therapies succeed.